Capstone Therapeutics Corp. (NASDAQ:CAPS) Short Interest Update

Capstone Therapeutics Corp. (NASDAQ:CAPS) saw a significant decline in short interest during the month of August. As of August 14th, there was short interest totaling 190,290 shares, a decline of 39.0% from the July 30th total of 311,827 shares. Currently, 1.5% of the shares of the company are sold short. Based on an average daily trading volume, of 1,508,069 shares, the short-interest ratio is presently 0.1 days.

Wall Street Analyst Weigh In

Separately, Weiss Ratings lowered Capstone Therapeutics from a “sell (e+)” rating to a “sell (e)” rating in a report on Thursday, August 20th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock has an average rating of “Sell”.

Capstone Therapeutics Price Performance

Shares of NASDAQ CAPS opened at $0.18 on Monday. The stock has a market cap of $3.77 million, a P/E ratio of -0.05 and a beta of -1.52. The firm’s 50-day simple moving average is $0.24 and its 200 day simple moving average is $0.40. Capstone Therapeutics has a fifty-two week low of $0.17 and a fifty-two week high of $1.57. The company has a quick ratio of 0.39, a current ratio of 0.99 and a debt-to-equity ratio of 0.69.

Institutional Trading of Capstone Therapeutics

An institutional investor recently bought a new stake in Capstone Therapeutics stock. DRW Securities LLC acquired a new stake in shares of Capstone Therapeutics Corp. (NASDAQ:CAPS) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 125,422 shares of the company’s stock, valued at approximately $91,000. DRW Securities LLC owned 1.51% of Capstone Therapeutics at the end of the most recent reporting period. 2.55% of the stock is currently owned by institutional investors.

About Capstone Therapeutics

Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.